Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Gastrointestinal stromal tumor presenting as lung mass: A case report

Joint Event on 5th Edition of International Conference on Clinical Oncology and Molecular Diagnostics & 5th World Congress on Medical Imaging & Clinical Research
June 17-18, 2019 Rome, Italy

Kristine Anne B Monte

Cardinal Santos Medical Center, Philippines

Posters & Accepted Abstracts: Arch Cancer Res

Abstract:

Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract commonly seen in middleaged and elderly adults with the most common location in the stomach and small intestine. These tumors most frequently metastasize to the liver and peritoneum and it is relatively rare that the tumor invades the lung and the bones. GISTs outside the gastrointestinal tract appear to relapse more frequently. The treatment of unresectable GISTs is systemic treatment with tyrosine kinase inhibitors. We present a case of a 20-year-old Filipino male with a 2-week history of exertional dyspnea which on work up showed a left pulmonary mass consistent with a high grade gastrointestinal stromal tumor with no evidence of intra-abdominal GIST on work-up. Immunohistochemistry revealed spindle cells positive for CD 117, DOG-1, and CD 56, negative for CK, TTF-1, SMA, desmin, S-100, and CD34. He underwent attempted video assisted thoracoscopic surgery (VATS), open thoracotomy, lung mass biopsy, tumor debulking and decortication and began treatment with oral imatinib mesylate (Gleevec) at a dose of 400 mg/ day but was refractory after 3 months of treatment. The patient had pulmonary infection and evidence of tumor progression at that time. He then underwent radiotherapy and a second line pazopanib 400 mg/day was started. Partial response was achieved after two to three months. The patient is currently stable and with good functional capacity.

Biography :

E-mail:

kristine.anne.monte@gmail.com